Benefits of PARP Inhibitor Use in Breast Cancer

Video

Jennifer Litton, MD, Breast Medical Oncologist, MD Anderson Cancer Center, describes how PARP inhibitors compare to standard of care in breast cancer treatment.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with brown hair and bangs, surrounded by a blue border
Photo of an open bottle of pills
4 experts in this video
4 experts in this video
Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
Related Content
Photo of a person in a bathroom holding their abdomen and mouth

Adding Aprepitant to Chemo Extends Non-Luminal Breast Cancer Survival

Bridget Hoyt
August 2nd 2025
Article

Adding aprepitant to chemotherapy was linked to longer survival in patients with non-luminal breast cancers, especially triple-negative breast cancer.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
August 2nd 2025
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Graphic of a person with a breast tumor

Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

Bridget Hoyt
August 2nd 2025
Article

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
August 2nd 2025
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Graphic of a breast with a tumor

Olanzapine/Triplet Cuts Chemotherapy-Induced Nausea, Vomiting in Breast Cancer

Roman Fabbricatore
August 2nd 2025
Article

Those who took olanzapine reported higher levels of satisfaction than patients on placebo.

graphic of a breast with a tumor

KN026/KN046 Combo Yields Durable Responses in HER2+ mBC

Jax DiEugenio
August 2nd 2025
Article

KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.